U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Algunas Inc., dba Woodland Hills Compounding Pharmacy - 532739 - 03/25/2020
  1. Warning Letters

CLOSEOUT LETTER

Algunas Inc., dba Woodland Hills Compounding Pharmacy MARCS-CMS 532739 —

Delivery Method:
Via Email

Recipient:
Recipient Name
Dr. Steven A. Levin
Recipient Title
CEO and Owner
Algunas Inc., dba Woodland Hills Compounding Pharmacy

20631 Ventura Blvd.
Suite 305
Woodland Hills, CA 91364
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

949-608-2900

Dear Dr. Levin:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 532739) dated July 17, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV